首页> 外文期刊>Iranian red crescent medical journal >Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis
【24h】

Case Report of a Patient Undergoing Peritoneal Dialysis with Encapsulating Peritoneal Sclerosis Superimposed With Calciphylaxis

机译:腹膜透析合并糖化治疗的腹膜透析患者的病例报告

获取原文
获取外文期刊封面目录资料

摘要

Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials. Case Presentation: Herein, we report a case of a patient undergoing 12 years of PD who developed EPS and calciphylaxis simultaneously. We also provide a comprehensive discussion about the association between EPS and calciphylaxis. Moreover, although tamoxifen is used in EPS due to its inhibition of fibroblast-transforming growth factor beta (TGFβ) production, it may worsen the calciphylaxis due to a hypercoagulable state. Conclusions: We suggest avoiding the use of tamoxifen for EPS in patients with superimposed calciphylaxis.
机译:封装性腹膜硬化症(EPS)是一种罕见但具有破坏性的腹膜透析(PD)并发症。他莫昔芬的耐受性一般良好,即使没有随机对照试验也是如此。病例介绍:在此,我们报道了一名患有12年PD的患者,该患者同时发生EPS和钙化。我们还提供了有关EPS与钙化的关联的全面讨论。此外,尽管由于他莫昔芬抑制成纤维细胞转化生长因子β(TGFβ)的产生而被用于EPS,但由于高凝状态,它可能会使钙化异常恶化。结论:我们建议避免合并他莫昔芬的患者使用他莫昔芬治疗EPS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号